Researchers Map 10,776 Blood Proteins in 1,298 People Over 20 Years
Updated
Updated · Nature.com · Aug 10
Researchers Map 10,776 Blood Proteins in 1,298 People Over 20 Years
2 articles · Updated · Nature.com · Aug 10
Summary
A 20-year longitudinal study tracked 10,776 blood protein markers in 1,298 adults and produced what researchers call the first comprehensive map of long-term proteomic stability.
The data showed wide differences in how stable proteins remain within individuals over time, unlike routine clinical markers, with stability largely preserved across sex and life stage.
Highly stable proteins were more strongly tied to genetics and circulation-related functions such as immune regulation, letting researchers use them as individual biological fingerprints.
Using UK Biobank validation, the team built a sparse protein panel that improved biological age prediction, separated stable from volatile cardiovascular and dementia risk markers, and identified 21 proteins whose deviations independently predicted mortality.
The findings position personalized blood-protein baselines as a potential tool for detecting early disruption of homeostasis and advancing blood-based precision medicine.
Could a simple blood test revealing your unique 21-protein baseline accurately predict your hidden mortality risks and true biological age?
Why do some blood proteins remain perfectly stable for decades while others quietly signal the early onset of cardiovascular disease and dementia?
If your blood proteins silently drift from their genetic baseline, is it an irreversible countdown to age-related disease or can you stop it?
20-Year Proteomic Study Reveals Dynamic Aging, Superior Disease Prediction, and the Ethical Frontier of Biological Risk Profiling
Overview
This report highlights how puberty triggers dramatic, sex-specific changes in blood proteins, making standard adult reference values unsuitable for children and adolescents. Because protein levels in children shift rapidly with age, establishing pediatric-specific reference ranges is essential to avoid misdiagnosis. The high cost of comprehensive proteomic profiling is driving the industry toward targeted, disease-specific panels for better affordability. On the ethical front, biological age profiling uses dynamic protein and epigenetic markers not covered by existing genetic protection laws, creating regulatory gaps. Notably, discrimination accelerates biological aging, and if insurers or employers use biological age data, those affected by discrimination could face further disadvantages.